Article Sidebar
Published:
Jan 11, 2025Keywords:
Article Details
While African Health Sciences has been freely accessible online there have been questions on whether it is Open Access or not. We wish to clearly state that indeed African Health Sciences is Open Access. There are key issues regarding Open Access needing clarification for avoidance of doubt:
- 1. Henceforth, papers in African Health Sciences will be published under the CC BY (Creative Commons Attribution License) 4.0 International. See details on https://creativecomons.org/)
- 2. The copyright owners or the authors grant the 3rd party (perpetually and in advance) the right to disseminate, reproduce, or use the research papers in part or in full, format/medium as long as:
- No substantive errors are introduced in the process
- Attribution of authorship and correct citation details are given
- The referencing details are not changed.
Should the papers be reproduced in part, this must be clearly stated.
- 3. The papers will be freely and universally accessible online in an easily readable format such as XML in at least one widely recognized open access repository such as PUBMED CENTRAL.
B. ABRIDGED LICENCE AGREEMENT BETWEEN AUTHORS AND African Health Sciences
I submitted my manuscript to African Health Sciences and would like to affirm that:
1.0 I am authorized by my co-authors to enter into these arrangements.
2.0 I guarantee, on behalf of self and co-authors:
- That the paper is original, and has not been published in any other peer-reviewed journal; nor is it under consideration by other journal (s). It does not infringe existing copyright or any other person’s rights
- That we are/I am the sole author(s) of the paper and with authority to enter into this agreement. My granting rights to African Health Sciences is not in breach of any other obligation
- That the paper contains nothing unlawful, or libelous. Nor anything that would constitute a breach of contract, confidence or commitment given to secrecy, if published
- That I/we have taken care to ensure the integrity of the article.
3.0 I and all co-authors, agree that the paper, if accepted for publication, shall be licensed under the Creative Commons Attribution License 4.0. (see https://creativecommons.org/)
Main Article Content
The predictive prognostic value of serum CEA, CA153, HE4 combined with a variety of immune inflammatory indicators in breast cancer
Abstract
Objective: To investigate the prognostic value of serum carcinoembryonic antigen (CEA), carbohydrate antigen (CA153), and human epididymal 4 (HE4) combined with a variety of immune inflammatory indicators in breast cancer.
Methods: A sample size of 112 breast cancer patients was selected and all patients underwent surgical treatment. The three year prognosis of the patients was observed. Patients with poor prognoses were included in the poor prognoses group and the patients with good prognosis were included in the good prognosis group. The levels of serum CEA, CA153, HE4, and related immune inflammatory indicators (including Mon, Lym, Neu, Plt, NLR, and SII) were analysed. The predictive value of serum CEA, CA153, HE4, and immune inflammatory indicators on the prognosis of breast cancer was analysed by Logistic regression and ROC curve method. The area under the ROC curve (AUC) was used to evaluate the predictive efficiency. α=0.05 was used as the test standard.
Results: Compared with the good prognosis group, the CEA, CA153, HE4, Mon, Neu, Plt, and SII of the poor prognosis group were higher, all P<0.05. Logistic regression analysis showed that CEA, CA153, HE4, Neu, and Plt were effective indicators for predicting the poor prognosis of breast cancer. The AUC of CEA, CA153, HE4, Neu, and Plt in predicting the prognosis of breast cancer was 0.929, which was higher than the AUC of a single prediction.
Conclusion: Serum CEA, CA153, HE4 combined with Neu and Plt had predictive value for the prognosis of breast cancer.
Keywords: Breast cancer; CA153; CEA; HE4; immune inflammatory indicators; predictive; prognostic.
